Arbutus Biopharma Corp (ABUS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 7 | 11 | 39 | 18 | 6 | 14 | - | - |
| Operating profit | $m | -27 | - | ||||||
| Net profit | $m | -64 | -76 | -69 | -73 | -70 | -34 | - | - |
| EPS reported | $ | -0.17 | - | ||||||
| Operating cashflow per share | $ | -0.21 | - | ||||||
| Capex per share | $ | 0.00 | - | ||||||
| FCF per share | $ | -0.21 | - | ||||||
| Free cash flow | $m | -40 | - | ||||||
| Net debt | $m | -87 | - | ||||||
| Book value equity | $m | 77 | - | ||||||
| Book value per share | $ | 0.40 | - | ||||||
| Number of shares | m | 191.6 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 12.04 | - | ||||||
| P/S LTM | x | 65.44 | - | ||||||
| P/FCF LTM | x | -23.25 | - | ||||||
| EV/EBITDA LTM | x | -27.47 | - | ||||||
| EV/Sales LTM | x | 64.46 | - | ||||||
| Earnings Yield LTM | % | -3.64% | - | ||||||
| FCF Yield | % | -4.30% | - | ||||||
| Quality | |||||||||
| ROE | % | -43.75% | - | ||||||
| ROIC | % | -30.34% | - | ||||||
| Operating margin | % | -1.92% | - | ||||||
| Gross margin | % | +97.42% | - | ||||||
| FCF/Sales | % | -281.45% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +128.21% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -9.46 | - | ||||||
| Net Debt/EBITDA | x | 0.42 | - | ||||||
| EBIT/Net interest | x | -278.88 | - | ||||||
| Net debt/market cap | % | +0.43% | - | ||||||
| Net debt/Equity | x | -1.14 | - | ||||||
| Gross debt/equity | x | 0.05 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free